A.G.E. Crosslink Breakers for Ocular Disorders

Paul Kaufman, MD
University of Wisconsin Madison (Madison, WI)
Year Awarded:
2005
Grant Duration:
April 1, 2005 to March 31, 2007
Disease:
Glaucoma
Award Amount:
$89,866
Grant Reference ID:
G2005004
Award Type:
Standard
Award Region:
US Midwestern

A.G.E. Crosslink Breakers for Ocular Disorders

Details

Dr. Kaufman will determine whether the crosslink breaker compound, alagebrium, can alter intraocular pressure, improve the ease with which fluid passes out of the eye (outflow facility) via the conventional outflow pathways, and improve the ability to focus in response to a pharmacologic stimulus. Completion of these studies will clarify whether crosslink breaker compounds have any promise for further development as therapies for primary open angle glaucoma or presbyopia, the age-related loss of focal ability. This type of therapy would target a different pathway than all other glaucoma therapeutics and create the first pharmacologic therapy for presbyopia.
Don't miss out.
Receive research updates, inspiring stories, and expert advice
Please enter your first name.
Please enter your last name.
Keep me informed about: *
Please select at least one.
You must select at least one disease category.